Great Lakes Advisors LLC Acquires Shares of 169,557 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Great Lakes Advisors LLC bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 169,557 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,131,000. Great Lakes Advisors LLC owned about 0.31% of Supernus Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SUPN. Pacer Advisors Inc. boosted its position in Supernus Pharmaceuticals by 29.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after purchasing an additional 403,028 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at $6,847,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Supernus Pharmaceuticals by 145.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,864 shares of the specialty pharmaceutical company’s stock worth $6,699,000 after buying an additional 127,420 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Supernus Pharmaceuticals by 14.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after buying an additional 91,354 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after buying an additional 74,438 shares in the last quarter.

Insider Buying and Selling

In other news, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 in the last 90 days. Insiders own 9.30% of the company’s stock.

Analysts Set New Price Targets

SUPN has been the topic of several recent analyst reports. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 8th.

Supernus Pharmaceuticals Stock Down 0.7 %

SUPN opened at $31.17 on Friday. The firm’s fifty day simple moving average is $36.44 and its two-hundred day simple moving average is $35.22. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The company has a market cap of $1.74 billion, a price-to-earnings ratio of 29.13 and a beta of 0.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.